Add Content...

Anti-PSA Prostate Cancer Program (IgG & IgE)

Products Under Development * Anti-PSA Prostate Cancer Program (IgG & IgE)

The prostate-specific antigen (PSA), often found at high levels in the serum of Prostate Cancer patients, has been used as a marker for Prostate Cancer detection and as a target of immunotherapy.

Oncoquest pipeline contains both IgG and IgE antibodies against the PSA antigen that can be developed from the immunotherapy of Prostate Cancer.

The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. Preclinical studies with MAb AR47.47 in animal tumor control studies showed synergistic effects for combination cyclophosphamide-IT over single agents. 

Tumor Control of ProstaRex, Cyclophosphamide and the Combination Thereof in PSA-Transgenic Mice Bearing PSA-Expressing Tumors

Oncoquest’s anti-PSA IgE is licensed from UCLA and preclinical studies have shown that when combined with PSA, it can trigger immune activation in vitro and in vivo and significantly prolongs the survival of human FcεRIα transgenic mice challenged with PSA-expressing tumors in a prophylactic vaccination setting.

 

Median survival of animals in the vaccination study in human FcεRIα transgenic mice 

 

Median survival
(days)

p-value
(compared to buffer control)

p-value
(compared to PSA)

p-value
(compared to PSA + anti-PSA IgG1)

Buffer

14.5

 

 

 

PSA

15

0.777

 

 

PSA + anti-PSA IgG1

16

0.086

0.147

 

PSA + anti-PSA IgE

22

0.004

0.005

0.01

 

Data shown are combined from two independent experiments (n = 4 for each) with a total of 8 animals per group.

Oncoquest Prostate Cancer Program